期刊文献+

血清胱抑素C对初诊帕金森病患者轻度认知损害的早期诊断价值 被引量:10

Diagnostic value of serum cystatin C on newly diagnosed Parkinson's disease with mild cognitive impairment
在线阅读 下载PDF
导出
摘要 目的探讨血清胱抑素C(Cys-C)表达变化对初诊帕金森病患者轻度认知损害的早期诊断价值。方法共101例初诊帕金森病患者分为帕金森病轻度认知损害组(PD-MCI组,43例)和帕金森病认知功能正常组(对照组,58例),循环酶法检测血清Cys-C、脂质、肌酐和尿酸水平,简易智能状态检查量表(MMSE)和蒙特利尔认知评价量表(Mo CA)评价认知功能;Logistic回归分析评价血清Cys-C与认知功能间的相关性;受试者工作特征曲线(ROC曲线)计算血清Cys-C早期诊断帕金森病轻度认知损害之灵敏度、特异度和准确率。结果 PD-MCI组患者血清Cys-C水平高于对照组[(1.12±0.10)mg/L对(1.00±0.15)mg/L,P=0.000]。各项危险因素筛查仅血清Cys-C为帕金森病患者轻度认知损害的独立危险因素(OR=4.285,95%CI:1.301-14.112;P=0.017),且与MMSE总评分(rs=-0.831,P=0.000)和Mo CA总评分(rs=-0.848,P=0.000),以及视空间能力和执行功能(rs=-0.495,P=0.001)、注意力和计算力(rs=-0.339,P=0.026)、延迟回忆(rs=-0.307,P=0.045)评分均呈负相关;ROC曲线下面积为0.707(95%CI:0.603~0.811,P=0.000),诊断灵敏度和特异度分别为53.50%和82.80%,所对应的血清Cys-C临界值为1.105 mg/L。结论血清Cys-C表达水平升高可能与初诊帕金森病患者轻度认知损害密切相关,具有早期诊断参考价值。 Objective To investigate the diagnostic value of expression level of serum cystatin C(Cys- C) on early diagnosis of newly diagnosed Parkinson's disease with mild cognitive impairment(PD-MCI).Methods A total of 101 PD patients were divided into 2 groups: PD-MCI gruop(N = 43) and PDwith normal cognition group(control group, N = 58). The levels of serum Cys-C, lipid, creatinine(Cr) anduric acid(UA) were tested. Mini-Mental State Examination(MMSE) and Montreal Cognitive Assessment(Mo CA) were used to evaluate cognitive function, and Logistic regression analysis was used to evaluate thecorrelation between PD-MCI and the level of serum Cys-C. Receiver operating characteristic(ROC) curvewas used to detect the sensitivity and specificity of early diagnosis.Results The expression level ofsPe rum Cys-C in PD-MCI group [(1.12 ± 0.10) mg/L] was higher than that of control group [(1.00 ± 0.15) mg/L,= 0.000]. Univariate and multivariate Logistic regression analysis showed that serum Cys- C was theindependent risk factor for PD- MCI(OR = 4.285, 95% CI: 1.301-14.112; P = 0.017); Spearman rankcorrelation analysis showed the expression level of serum Cys-C was negatively correlated with MMSE totalscore(rs=- 0.831, P = 0.000), Mo CA total score(rs=- 0.848, P = 0.000), visuospatial/executive function(rs=- 0.495, P = 0.001), attention/counting(rs=- 0.339, P = 0.026) and delayed recall(rs=- 0.307, P P = 0.045).ROC curve analysis showed that area under the curve(AUC) was 0.707(95%CI: 0.603-0.811, = 0.000).Diagnostic sensitivity and specificity were 53.50% and 82.80% respectively, and the critical value of serumCys- C level was 1.105 mg/L.Conclusions Increased expression level of serum Cys- C maybe closelyrelated with newly diagnosed PD-MCI, and has a certain value to the early diagnosis of PD-MCI.
出处 《中国现代神经疾病杂志》 CAS 2015年第8期638-644,共7页 Chinese Journal of Contemporary Neurology and Neurosurgery
基金 科技部"重大新药创制"重大专项项目(项目编号:2012ZX09303-003) 科技部"重大新药创制"重大专项项目(项目编号:2012ZX09303005-002) 国家自然科学基金资助项目(项目编号:81471215) 国家自然科学基金资助项目(项目编号:81271211) 国家自然科学基金资助项目(项目编号:30700248) 江苏省科技支撑计划项目(项目编号:BE2011614) 江苏省重点实验室开放课题(项目编号:SJ11KF05) 江苏省"333高层次人才培养工程"资助项目[项目编号:(2013)Ⅲ-0077号] 江苏省"六大人才高峰"资助项目(项目编号:2012-WS-002) 江苏省扬州市"绿扬金凤计划"创新领军人才项目(项目编号:yzlyjfjh2013CX056)~~
关键词 半胱氨酸蛋白酶抑制剂 帕金森病 认知障碍 危险因素 回归分析 Cysteine proteinase inhibitors Parkinson disease Cognition disorders Riskfactors Regression analysis
  • 相关文献

参考文献23

  • 1Wang YQ, Tang BS, Yan XX, Chen ZH, Xu Q, Liu ZH, Li K, Wang K, Guo JF. A neurophysiological profile in Parkinson's disease with mild cognitive impairment and dementia in China. J Clin Neurosci, 2015, 22:981-985.
  • 2Aarsland D, Brcnnick K, Larsen JP, Tysnes OB, Alves G; Norwegian ParkWest Study Group. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest Study. Neurology, 2009, 72:1121-1126.
  • 3Yarnall AJ, Breen DP, Duncan GW, Khoo TK, Coleman SY, Firbank M J, Nombela C, Winder-Rhodes S, Evans JR, Rowe JB, Mollenhauer B, Kruse N, Hudson G, Chinnery PF, O'Brien JT, Robbins TW, Wesnes K, Brooks DJ, Barker RA, Burn DJ; ICICLE - PD Study Group. Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE- PD Study. Neurology, 2014, 82:308-316.
  • 4Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord, 2008, 23:837-844.
  • 5Kaur G, Levy E. Cystatin C in Alzheimer's disease. Front Mol Neurosci, 2012, 5:79.
  • 6Bever CT Jr, Panitch HS, Johnson KP. Increased cathepsin B activity in peripheral blood mononuclear cells of muhiple sclerosis patients. Neurology, 1994, 44:745-748.
  • 7Zeng Q, Lin K, Yao M, Wei L. Significant correlation between cystatin C, cerebral infarction, and potential biomarker for increased risk of stroke. Curr Neurovasc Res, 2015, 12:40-46.
  • 8陈荣波,陈文杰,郑璇.胱氨酸蛋白酶抑制剂C与缺血性卒中的相关性研究[J].中国现代神经疾病杂志,2013,13(6):533-537. 被引量:4
  • 9中华医学会神经病学分会运动障碍及帕金森病学组.帕金森病的诊断.中华神经科杂志,2006,39:408-409
  • 10Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol, 1999, 56:303-308.

二级参考文献18

  • 1各类脑血管疾病诊断要点[J].中华神经科杂志,1996,29(6):379-380. 被引量:33091
  • 2方军,洪灵敏.急性脑梗死患者血清胆红素和胱抑素C水平变化及意义[J].中国实验诊断学,2007,11(6):835-836. 被引量:35
  • 3Eriksson P, Deguchi H, Samnegfird A, Lundman P, Rotjuisl S,Tornvall P, Ericsson CG, Bergstrand L, Hansson L(), Ye S,Hamsten A. Human evidence that the cystatin C gene is implicatedin focal progression of coronary artery disease. Arteriosc^ler ThromhVase Biol, 2005, 24:551-557.
  • 4Reed CH. Diagnostic applications of cystatin C. Rr J Biomed Sci.2000, 57:323-329.
  • 5Seliger SK, Longstreth WT Jr, Katz R, Manolio T, Fried LF,Shlipak M, Stehman-Breen CO, Newman A, Sarnak M, Gillen DL,Bleyer A, Siscovick DS. Cystatin C and suhclinica! braininfarction. J Am Soc Nephrol, 2005, 16:3721-3727.
  • 6Randers E, Krue S, Erlandsen EJ, Danielsen H, Hansen LG.Reference interval for serum cystatin C in children. Clin Chem,1999, 45:1856-1858.
  • 7Ni T,,Lii J, Hou LB, Yan JT, Fan Q, Hui R, Cianflone K, WangW, Wang DW. Cystalin C, associated with hemorrhagic andischemic stroke, is a strong predictor of the risk of cardiovascularevents and death in Chinese. Stroke, 2007,37:3287-3288.
  • 8Hasegawa A, Naruse M, Hitoshi S, hvasaki 1 A, Takebayashil H,Ikenaka K. Regulation of glial development by Cystatin C. JNeurochem, 2007, 100:12-22.
  • 9Kaeser SA, Herzig MC, Coomaraswamy J, et al. Cystatin C modulates cerebral beta - amyloidosis. Nat Genet ,2007,39 : 1437-1439.
  • 10Mi W, Pawlik M,'Sastre M, et al. Cystatin C inhibits amyloid beta deposition in Alzheimer, s disease mouse models. Nat Genet,2007, 39 : 1440-1442.

共引文献5

同被引文献102

引证文献10

二级引证文献90

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部